Table 2

Structural disease progression at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARD or MTX

Concomitant
treatment
cDMARDMTXNone
(cDMARD-naïve or past use at baseline)
PBO, n=58IXEQ4W, n=63IXEQ2W, n=60PBO, n=48IXEQ4W, n=52IXEQ2W, n=49PBO,
n=35
IXEQ4W, n=37IXEQ2W, n=37
mTSS LSM change from baseline at week 24 (SE)0.44
(0.100)
0.11
(0.096)*
0.11
(0.098)*
0.52
(0.135)
0.13
(0.121)*
0.14
(0.114)*
0.57
(0.157)
0.25
(0.153)
0.03
(0.153)*
  • The study was not designed to test equivalence or non-inferiority of treatment with ixekizumab alone versus treatment with ixekizumab with concomitant cDMARDs.

  • *P<0.05 versus PBO.

  • cDMARD, conventional disease-modifying antirheumatic drugs; IXEQ2W, 80 mg ixekizumab once every 2 weeks; IXEQ4W, 80 mg ixekizumab once every 4 weeks; LSM, least squares mean; mTSS, van der Heijde modified total Sharp score; MTX, methotrexate; n, number of patients; PBO, placebo.